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Some murine-endogenous retroviruses, making up ~10% of the mouse genome, are induced
during the course of experimental sepsis in which lipopolysaccharide (LPS), a pathogenic
component of Gram-negative bacteria, often plays a critical role. In this study, we investigated
whether LPS stress induces the production of murine leukemia virus type-endogenous retrovirus
(MuLV-ERV) virions in primary lymphoid cells. LPS treatment of cells (single-cell suspensions and
sorted B- and T-cells) isolated from seven lymphoid organs of C57BL/6J mice resulted in a
differential increase in the production of MuLV-ERV virions in most cells examined. Interestingly,
among the 34 unique MuLV-ERV U3 sequences cloned from the viral genomic RNAs, the nuclear
respiratory factor 1 (transcription factor) element was present only in the 20 U3 sequences that
were derived from the LPS-induced MuLV-ERV U3 bands. Using the U3 sequences as a probe,
55 putative MuLV-ERV loci were mapped onto the C57BL/6J mouse genome and 15 of them
retained full coding potential. Furthermore, one full-length recombinant MuLV-ERV originating
from a locus on chromosome 13 was determined to be responsive to LPS stress. The findings
from this study suggest that LPS stress differentially activates MuLV-ERV virion production in
lymphoid organs in a cell type- and MuLV-ERV-specific manner. Further investigation is needed to
define the role of MuLV-ERVs in the LPS signalling pathway(s) in general, as well as in the
pathogenesis of sepsis.
INTRODUCTION
Infection of germ-line cells during the early stages of
embryonic development by exogenous retroviruses allows
for the permanent embedment of their proviral copies,
called endogenous retroviruses (ERVs), into random loci of
the germ-line genome (Boeke & Stoye, 1997). ERVs, which
are passed to the offspring along with other genetic
information in the germ-line genome, are reported to be
present in all vertebrates examined so far and constitute ~8
and ~10% of the human and mouse genomes, respectively
(Griffiths, 2001; Herniou et al., 1998; Waterston et al.,
2002).
Like all the other genetic elements in the genome, the
ERVs’ biological activities are primarily governed by the
intracellular transcription environment, which is specific or
non-specific for individual cells (Larsson & Andersson,
1998). Regulatory elements found in individual ERV
promoters, which are located on the U3 region of the 59
LTR, play a crucial role in controlling ERV expression
within the transcription environment in which they reside
(Corcoran et al., 1984; Selten et al., 1985; Trusko et al.,
1989). The transcription environment is specifically and
dynamically formulated for the short- and/or long-term in
the individual cells, which are constantly subjected to
various stressors (both proximal and distal) such as injury,
infection and hormone change (Cho et al., 2008). Stressor-
elicited activation of certain murine leukemia virus type-
ERVs (MuLV-ERVs) may produce replication-competent
virus particles whose genomes are either full length or
defective (Kwon et al., 2009; Lee et al., 2007). These
‘activated’ virus particles have the potential to alter the
response to stressors, such as sepsis or injury.
Lipopolysaccharide (LPS), which is found on the surface of
Gram-negative bacteria, is one of the most extensively
studied triggers of innate immune response (Alexander &
Rietschel, 2001). Various cell types, such as fibroblasts,
immature B-cells, B-cells, T-cells, monocytes and macro-
phages, are susceptible to LPS stress (Chaby & Girard, 1993;
Morrison & Ulevitch, 1978). The binding of LPS to its
membrane receptor complex, primarily composed of
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intracellular events associated with the production of pro-
inflammatory cytokines and relevant pathogenic processes
(O’Neill, 2003). In addition, the mitogenic properties of LPS
are responsible for the initiation of proliferation and
differentiation of B-cells into antibody-producing plasma
cells in conjunction with V(D)J rearrangement of immu-
noglobulin genes (Yang et al., 2007).
A number of non-ecotropic MuLV-ERVs (i.e. xenotropic,
polytropic and modified polytropic) have been identified
and characterized in various mouse strains (Frankel et al.,
1990; Jern et al., 2007; Kwon et al., 2009; Lee et al., 2007,
2008; Stoye & Coffin, 1987). It has been reported that
certain endogenous xenotropic MuLVs are induced by LPS
stimulation in the spleen cells of several strains of mice
(Jongstra & Moroni, 1981; Kozak & Rowe, 1980; Krieg
et al., 1988; Phillips et al., 1976). These findings provide
evidence that LPS induces the expression of certain MuLV-
ERVs in lymphoid tissues.
Recent studies conducted in our laboratory have demon-
strated that stress signals elicited from burn injury or caecal
ligation and puncture (CLP)-induced sepsis differentially
altered the expression of MuLV-ERVs in a range of organs
(Cho et al., 2008, 2009). It has been proposed that post-
burn activation of Gram-negative bacterial activity in the
gut contributes to the elevation of systemic LPS levels
(Schwacha, 2003). In addition, LPS may play a critical role
in the development of sepsis following CLP-induced
polymicrobial peritonitis (Neviere et al., 1999). In this
study, we tested the hypothesis that, among a range of
stressors associated with the pathogenic processes of burn
and/or sepsis, LPS induces expression of certain MuLV-
ERVs in the cells of the lymphoid organs resulting in an
increase in virion production.
RESULTS AND DISCUSSION
LPS-induced increase in the production of MuLV-
ERV virions in a lymphoid organ- and cell type-
specific manner
To investigate whether LPS stress induces MuLV-ERV
virion production, primary cells derived from seven
lymphoid tissues [spleen, thymus, bone marrow and four
lymph nodes (axillary, cervical, inguinal and mesenteric)]
of C57BL/6J mice were treated with LPS. Supernatants
were collected from the LPS-treated and control primary
single-cell suspensions and subjected to RT-PCR analysis
for viral genomic RNA. A primer set for the MuLV-ERV
U3 promoter regions within the 39 LTR was used to
examine changes in the levels of viral genomic RNAs (Fig.
1a). One distinct U3-region band (~500 bp and labelled as
‘a’ in Fig. 1b) was amplified from viral genomic RNA from
all lymphoid tissues; however, the thymus had two
additional bands (~450 bp, labelled as ‘b’ in Fig. 1b and
~750 bp, labelled as ‘c’ in Fig. 1b). b-Actin was used as a
negative control to confirm that there was no cellular
mRNA contamination of the viral genomic RNAs isolated
from the supernatants. A quantitative analysis of the
amplification pattern of the ‘a’ band revealed that there was
a significant increase (denoted by *, P,0.05 and **,
P,0.01) in the level of MuLV-ERV genomic RNA in the
culture supernatants of LPS-treated single-cell suspensions,
which were derived from the bone marrow and three
lymph nodes (cervical, inguinal and mesenteric) (Fig. 1c).
These findings suggest that LPS stress differentially induces
production of MuLV-ERV virions, depending on the
source of the lymphoid cells. It is probable that by-
products of the well-studied LPS signalling pathway, such
as nuclear factor kB and inflammatory cytokines, may
participate in the activation of certain MuLV-ERVs (Lee
et al., 2008; Verstrepen et al., 2008). Alternatively,
transcription factors associated with unknown LPS signal-
ling event(s) may play a role in the activation of these
MuLV-ERVs, which in turn modulate the expression of
certain molecules, including inflammatory mediators (e.g.
interleukin-6 and cyclooxygenase-2). Furthermore, the
activated MuLV-ERVs may enact their biological functions
via their gene products (e.g. Env or Gag protein) and/or by
the infection of host cells in conjunction with random
genomic integration of their proviral copies (Dolei, 2005;
Knerr et al., 2004; Mi et al., 2000).
To identify the specific cell type(s) in the tissues
responsible for the increased production of MuLV-ERV
virions in response to LPS treatment, the primary cells
from the seven lymphoid organs were sorted into B- and T-
cells. These sorted cells were also treated with LPS and the
supernatants were collected and analysed for the presence
of MuLV-ERV genomic RNAs by RT-PCR (Fig. 1b and c).
Significant and differential increases (denoted by *, P,0.05
and **, P,0.01) in the levels of MuLV-ERV genomic RNA
(‘a’ band) were observed in the supernatants of LPS-treated
B-cells isolated from all lymphoid organs except for the
thymus (Fig. 1b and c). Among the B-cell populations
originating from four different lymph nodes, B-cells from
the inguinal and mesenteric lymph nodes displayed a
substantially greater response to LPS treatment, in regard
to MuLV-ERV virion production, compared with the other
two lymph nodes. Interestingly, the supernatants of the
LPS-treated immature T-cells derived from the bone
marrow had an evident increase in the level of MuLV-
ERV genomic RNA compared with the no-treatment
control.
The results from these experiments suggest that the B-cells
residing in both central and peripheral immune organs are
the main producers of MuLV-ERV virions in response to
LPS stress, and the response is variable depending on the
location of the lymphoid organs. Previous reports indicate
that B-cells’ response to LPS stress is variable depending on
their locations, and leads to proliferation and differenti-
ation into antibody-producing plasma cells (Kozak &
Rowe, 1980; Phillips et al., 1976; Skalet et al., 2005; Yang
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contributes to the B-cells’ variable response to LPS stress,
such as C57BL/6J (high LPS responder) versus BALB/c
(low LPS responder) (Andersson et al., 1977; Wells et al.,
2003). It may be interesting to examine whether the
MuLV-ERV induction profile of B-cells derived from
BALB/c mice in response to LPS stress is different from the
profile observed in C57BL/6J mice in this study.
To confirm further that LPS stress contributes to the
increase in production of MuLV-ERV virions, the levels of
viral genomic RNA and mRNA were examined in culture
supernatants and cell extracts of primary splenocytes,
respectively, following LPS treatment (Fig. 1d). The
presence of MuLV-ERV virions in the supernatants was
shown by the detection of substantial levels of viral
genomic RNAs by RT-PCR in the absence of evident
Fig. 1. Differential induction of MuLV-ERV production in cells derived from various lymphoid organs in an organ- and cell type-
specific manner. (a) Schematic representation of primer locations. A set of primers (ERV-U2 and ERV-U1) flanking the 39 U3
region of a typical retroviral provirus are indicated by arrows. (b) RT-PCR analysis of changes in MuLV-ERV genomic RNA levels
after LPS treatment in culture supernatants of primary cells derived from various lymphoid organs. Post-LPS treatment changes
in the levels of MuLV-ERV genomic RNAs in the culture supernatants of primary cells [single-cell suspensions (left) and sorted
B- and T-cells (right)] of seven lymphoid organs were analysed by RT-PCR. SP, Spleen; TH, thymus; BM, bone marrow; CL,
cervical lymph node; IL, inguinal lymph node; ML, mesenteric lymph node; AL, axillary lymph node; a–c, different sizes of
amplified U3 bands. (c) Quantitative presentation of the results (shown in b) from RT-PCR analysis of MuLV-ERV genomic RNA
levels in the culture supernatants of primary cells (left graph, single-cell suspensions; right graph, sorted B- and T-cells). Density
of the amplified U3 bands from each group were presented as mean±SD. Statistical significance is indicated by: *, P,0.05 and
**, P,0.01. (d) RT-PCR analysis of MuLV-ERV genomic RNA from supernatants and mRNA from cell extracts of splenocyte
cultures following LPS treatment. Using both b-actin and GAPDH as cellular mRNA controls, the presence of viral genomic
RNA derived from the MuLV-ERV virions harvested from the culture supernatants was confirmed by RT-PCR. P, Positive
control, SC-1/MuLV LP-BM5 cell; N, negative control, HEK293 cell-vehicle treatment; S-C, splenocyte-vehicle treatment; S-L,
splenocyte-LPS treatment; SM, size marker. (e) Western blot analysis of MuLV-ERV Env protein in the culture supernatants of
splenocytes following LPS treatment. Presence of MuLV-ERV virions in the culture supernatants of splenocytes following LPS
treatment was confirmed by the detection of Env protein derived from MuLV-ERV virions. P, Positive control, SC-1/MuLV LP-
BM5 cell; N, negative control, HEK293 cell-vehicle treatment; S-C, splenocyte-vehicle treatment; S-L, splenocyte-LPS
treatment.
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dehydrogenase (GAPDH). Both mRNA and genomic RNA
levels of LPS-responsive MuLV-ERVs were increased in the
LPS treatment group; however, no significant differences in
the levels of b-actin and GAPDH in cell extracts were
observed between control and LPS-treatment groups,
confirming MuLV-ERV-specific induction. In addition,
the production of MuLV-ERV virions by the LPS-treated
splenocytes was substantiated by the detection of Env
protein in the supernatants (Fig. 1e). Since we anticipated
that a number of Env polypeptide variants (both known
and unknown) exist in C57BL/6J mice, it is unclear which
Env variants are represented in this blot.
Characteristics of U3 sequences derived from
MuLV-ERV genomic RNAs
To examine the structure of the U3 regions of viral
genomic RNA and to map the corresponding proviral loci
on the genome, the amplified MuLV-ERV bands from the
supernatants of single-cell suspensions and sorted B- and
T-cells (both LPS treated and not treated) were sequenced.
It should be noted that the sequence data represents the U3
regions of MuLV-ERV genomic RNAs near the 39 end;
however, the 39 U3 region is presumed to be almost
identical to the 59 U3 region, which serves as a promoter in
non-rearranged proviruses. The data obtained from this
analysis revealed unique structural features among the
different U3 size groups. From a total of 124 U3 sequences
initially cloned from the three U3 bands (a, b and c), 34
unique sequences spanning five different sizes were
identified. The majority (20 of 34 U3 sequences) were
406 bp in size (derived from the ‘a’ band), in which three
direct repeats (1/1*, 5/5* and 6/6*) were present (Fig. 2a)
(Tomonaga & Coffin, 1998, 1999). An insertion of 190 bp
(complete or partial) and two direct repeats (1/1* and 6/
6*) were found in all U3 sequences derived from the
thymus ‘c’ band (556/600 bp in size). The U3 sequences of
346 bp in size, derived from the thymus ‘b’ band, had three
direct repeats (1/1*, 4/4* and 6/6*) (Supplementary Fig. S1,
available in JGV Online). Furthermore, phylogenetic
analysis of the 34 unique U3 sequences revealed three
main branches primarily clustered according to the size of
the U3 sequences (Fig. 2b).
To examine the transcription potential of the 34 unique
MuLV-ERV U3 sequences, the profile of putative tran-
scription regulatory elements within each U3 sequence was
surveyed (Supplementary Table S1, available in JGV
Online). Among the 70 regulatory elements mapped, nine
elements were shared by all 34 U3 sequences examined.
Interestingly, one element specific for the binding of
nuclear respiratory factor 1, (NRF1; Scarpulla, 1997) was
only present in all 20 of the U3 sequences of 406 bp in size,
which was one of the two size groups (406 and 433 bp)
isolated from the ‘a’ band. The ‘a’ band was induced
following LPS treatment in all lymphoid organs examined,
except the thymus (Fig. 1b). The primary function of the
NRF1 transcription factor is to regulate expression of
nucleus-encoded subunits of the cytochrome c oxidase
complex embedded in the mitochondrial membrane (Dhar
et al., 2008; Evans & Scarpulla, 1990). NRF1 is also
reported to bind to the promoter of hepatitis B virus X
gene, which plays a role in the regulation of mitochondrial
membrane potential (Tokusumi et al., 2004). Further
investigation is needed to evaluate whether NRF1 and
other transcription factors/co-factors play a specific role in
the transcriptional activation of the MuLV-ERVs harbour-
ing these unique U3 sequences in response to LPS stress.
In silico mapping of putative MuLV-ERVs using U3
sequences as a probe and characterization of
their biological properties
In order to identify the MuLV-ERVs harbouring each unique
U3 sequence, the National Center for Biotechnology
Information (NCBI) mouse-genome database was surveyed
using the 34 unique U3 sequences as data-mining probes.
MuLV-ERVs with greater than98% identity,respective to the
U3 probes, were mapped on various contiguous sequences of
the database (Supplementary Table S2, available in JGV
Online). A total of 56 MuLV-ERVs, ranging from 5312 to
9054 bp in proviral size, were identified and found to be
distributed throughout the genome except for chromosome
17(Supplementary Table S2).During chromosomalmapping
of the 56 MuLV-ERVs using the Mouse BLAT search program
(http://genome.ucsc.edu/), it was confirmed that 55 of them
were present in the C57BL/6J mouse genome, while MuLV-
ERV 34 was found within the SPRET/Ei mouse genome.
Fifty-three of the 56 MuLV-ERVs have been reported in our
previous studies (Kwon et al., 2009; Lee et al., 2007, 2008). In
addition, 38 of the 56 MuLV-ERVs were found to be
identical to ERVs reported previously (Supplementary Table
S2) (Frankel et al., 1990; Jern et al., 2007). For each MuLV-
ERV isolate, the complete proviral sequence plus flanking
sequences (50 bp upstream and downstream) were sub-
jected to the following analyses: ORF for coding potential,
primer-binding site (PBS) for replication initiation, target
site duplication (TSD) for recombination potential and
LTR mutation rate for the estimated integration age
(Supplementary Fig. S2, available in JGV Online).
In order to determine the coding potential of each MuLV-
ERV isolate, the ORFs for gag, pol and env polypeptides
were compared to the MuLV references (Supplementary
Table S2) (Shinnick et al., 1981; Urisman et al., 2006).
Fifteen of the 56 putative MuLV-ERVs retained intact
coding sequences for all three polypeptides (gag, pol and
env), while the rest had defective and/or partial ORFs for
some or all of the polypeptides.
A stretch of 18 bp immediately downstream of the 59 U5
region was examined to determine the PBS for each
putative MuLV-ERV isolate by comparing it to the
reference sequences (Harada et al., 1979; Nikbakht et al.,
1985). Glutamine tRNA binding sites were identified in 53
of the MuLV-ERVs, while threonine tRNA-binding sites
LPS stress and increased MuLV-ERV virion production
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ERV 46 (Supplementary Table S2) (Jern et al. 2007).
To determine whether there was a genetic rearrangement
event(s) in the MuLV-ERV isolates since the initial
integration into the genome, the TSDs flanking the 59 and
39 ends of each proviral sequence were surveyed
(Supplementary Tables S2 and S3, available in JGV Online).
TSDs are formed during the genomic integration event and
any genomic rearrangements involving the proviral locus,
primarily recombination via LTRs, replaces the TSDs with
two different sequences (Sverdlov, 2000). Nine of the 56
MuLV-ERVs did not retain TSDs at their integration sites,
suggesting that they are rearranged MuLV-ERVs, while the
rest had TSDs of 4–12 bp. Alternatively, the absence of TSDs
in the nine MuLV-ERVs may reflect random point mutations
instead of rearrangement events. We were not able to confirm
the recombination status of the nine MuLV-ERVs by an LTR
phylogenetic analysis because of high sequence identity in
each set of flanking LTR sequences (Supplementary Fig. S3,
available in JGV Online). Interestingly, four of the nine
MuLV-ERVs retained intact ORFs for all three polypeptides.
The integration age of MuLV-ERVs was estimated based on
the mutation rate between the two flanking LTRs. Two
MuLV-ERVs were determined to have estimated inte-
gration ages of 2.2 million years (Myr) (0.29% mutation
rate) and 2.1 Myr (0.27% mutation rate). Both of them are
defective proviruses, probably because of the accumulation
of mutations in the coding sequences since their initial
integration into the germ line. Since 45 of the 56 MuLV-
ERVs had no mismatch between flanking LTRs
(Supplementary Fig. S3), their estimated integration age
was arbitrarily recorded as ,1 Myr. On the other hand, the
integration age of the rearranged MuLV-ERV isolates, as
evidenced by the absence of TSDs, was not determined
Fig. 2. Structural features and phylogenetic relationship of the 34 unique U3 sequences isolated from MuLV-ERV genomic
RNAs. (a) Sequence features of the 34 unique U3 sequences. Using an alignment protocol, sequence features [direct repeats
(1/1*, 4/4*, 5/5* and 6/6*), unique sequences (2 and TATA box) and an insertion (190 bp insertion)] were determined for each
U3 sequence (Tomonaga & Coffin, 1998, 1999). a, ‘a’ Band; b, ‘b’ band; c, ‘c’ band; ++, presence of direct repeat; +,
presence of single unit; P, partial; $, absence. (b) Phylogenetic relationship of the 34 unique U3 sequences. The phylogenetic
tree was established based on the multiple alignment data. The node values indicate the percentage probability for a specific
branching. Bar, 0.02 nucleotide substitutions per site.
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the calculation of the mutation rate of their LTR.
Identification of an LPS-responsive recombinant
MuLV-ERV
To further characterize MuLV-ERV LPS responsiveness,
three MuLV-ERVs, which were isolated by using two U3
sequences (406 and 433 bp in size) as a probe
(Supplementary Table S1), were cloned from C57BL/6J
genomic DNA using a primer set specific for the sequences
flanking each provirus. Among the three recombinant
MuLV-ERVs, two [MuLV-ERV 3 (406 bp U3) and MuLV-
ERV 7 (433 bp U3)] had intact coding sequences for all
three polypeptides (gag, pol and env) and one [MuLV-ERV
6 (433 bp U3)] retained an intact coding sequences for pol
and env only. Following transfection of the recombinant
MuLV-ERVs into HEK293 cells, Western blot analysis
using the cell extracts demonstrated varying levels of Env
polypeptide expression among the recombinant MuLV-
ERVs, with MuLV-ERV 3 having the greatest (Fig. 3a).
To evaluate LPS responsiveness, the recombinant MuLV-
ERVs were transfected into RAW264.7 alveolar macrophage
cells and treated with LPS for 24 h. It has been reported that
certain ecotropic and polytropic MuLVs are constitutively
produced in this cell line (Hartley et al., 2008). RT-PCR
analysis of the cell extracts revealed that LPS treatment
resulted in a decrease in expression of MuLV-ERVs
endogenous to RAW264.7 cells (Fig. 3b). In contrast,
expression of the recombinant MuLV-ERV 3 was substan-
tially augmented in the LPS treatment group compared with
the vehicle control, while no evident changes were observed
in the expression of the other two recombinants (MuLV-
ERV 6 and MuLV-ERV 7). The LTR sequences of the three
recombinant MuLV-ERVs were then subjected to alignment
analysis to identify sequence features unique for the MuLV-
ERV 3 LTR, especially in the U3 promoter region (Fig. 3c).
In addition to the binding site for NRF1, as discussed above
(Supplementary Table S1), two unique regions were
identified in MuLV-ERV 3 compared with the LTRs of
MuLV-ERV 6 and MuLV-ERV 7. The notion that these
sequence features, including the NRF1 binding site, may
contribute to the responsiveness of MuLV-ERV 3 to LPS
treatmentneedstobeevaluatedfurther.Theresultsobtained
from this experiment substantiate the finding that LPS stress
increases the transcriptional activity of certain MuLV-ERVs,
which reside in a specific genomic location and harbour
unique U3-sequence feature(s).
Fig. 3. Identification of a LPS-responsive recombinant MuLV-ERV. (a) Confirmation of Env-protein expression from three
recombinant MuLV-ERVs. Western blot analysis confirmed expression of Env protein in HEK293 cells transfected with the
recombinant MuLV-ERVs (MuLV-ERV 3, 6 and 7). NT, No transfection; pCR2.1, transfection of pCR2.1 plasmid. (b) Effect of
LPS treatment on the expression of recombinant MuLV-ERVs. RT-PCR analysis revealed that expression of the MuLV-ERV 3
recombinant, but not MuLV-ERV 6 and MuLV-ERV 7, increased in response to LPS treatment. Arrows indicate expression of
MuLV-ERVs originating from RAW264.7 cells. NT, No transfection. (c) Alignment analysis of the LTR sequences of three
recombinant MuLV-ERVs (MuLV-ERV 3, 6 and 7). In addition to the nuclear respiratory factor 1 (NRF1) site highlighted in grey,
two sequence regions uniquely identified in the MuLV-ERV 3 LTR are indicated (i) and (ii).
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LPS, a potent pathogenic molecule derived from Gram-
negative bacteria, plays a crucial role during the onset and
progression of sepsis. The mechanisms underlying sepsis
pathogenesis have not been clearly defined yet. However,
the involvement of LPS in inflammation has been
investigated extensively, focusing on a set of signalling
pathways. The findings from this study suggest that LPS
stress can differentially activate MuLV-ERVs leading to
virion production, primarily in B cells of a range of
lymphoid organs. It may be important to investigate the
roles of these MuLV-ERVs in LPS signalling events as well
as in the pathogenesis of Gram-negative bacterial sepsis.
METHODS
Preparation of primary cells, sorting and LPS treatment. Single-
cell suspensions were prepared from the lymphoid organs [spleen,
thymus, bone marrow and lymph nodes (axillary, cervical, inguinal
and mesenteric)] of female C57BL/6J mice (11–13 weeks old; The
Jackson Laboratory, Bar Harbor, ME, USA). The animal protocol was
approved by the Animal Use and Care Administrative Advisory
Committee of the University of California, Davis. The cells were
suspended in culture medium [RPMI 1640 (Invitrogen) supplemen-
ted with 10% FBS (J R Scientific) and 100 mg streptomycin ml
21 and
100 U penicillin G ml
21 (Invitrogen)] and adjusted to
8610
5 cells ml
21. In a separate experiment, the lymphoid cell
suspensions were subjected to sorting into B and T cells using Pan
B (anti-B220) and Pan T (anti-Thy1.2) magnetic beads (Invitrogen),
respectively, according to the manufacturer’s protocol. Cells (single-
cell suspensions and sorted) were incubated at 37
oC with 5% CO2
for 24 h followed by LPS treatment [5 mg (ml culture medium)
21]
RPMI 1640 served as a vehicle control for LPS treatment. SC-1/MuLV
LP-BM5 cells (NIH AIDS Research and Reference Reagent Program,
Germantown, MD, USA) and HEK293 cells served as positive and
negative controls for MuLV-ERV virion production, respectively. SC-
1/MuLV LP-BM5 and HEK293 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen) supplemented with
10% FBS and 100 mg streptomycin ml
21 and 100 mg penicillin
Gm l
21. Cells and culture supernatants were harvested for the
isolation of total RNA and viral genomic RNA, respectively.
Transfection and LPS treatment. RAW264.7 alveolar macrophage
cells were maintained in DMEM supplemented with 10% FBS
(Atlanta Biologicals), 100 units penicillin ml
21, 100 mg streptomy-
cin ml
21 and 100 mg gentamicin ml
21. Twenty-four hours prior to
transfection, cells (1610
6 cells) in DMEM with 10% FBS (Atlanta
Biologicals), but without antibiotics, were seeded on six-well plates.
Transient transfection of cells with each recombinant MuLV-ERV
construct was performed using FuGENE HD (Roche Applied Science)
according to the manufacturer’s instructions. Subsequently, cells were
incubated at 37
oC with 5% CO2 for 24 h followed by a change of
culture medium with or without LPS (5 mgm l
21). DMEM culture
medium served as a vehicle control for LPS treatment. Cells were
harvested for total RNA isolation followed by RT-PCR. To confirm
the expression of Env protein from the individual recombinant
MuLV-ERV constructs, HEK293 cells were maintained in DMEM as
described above and transfection was performed using FuGENE 6
(Roche Applied Science) according to the manufacturer’s protocol. At
2 days post-transfection, the cells were harvested for Western blot
analysis. No transfection and transfection with pCR2.1 expression
plasmid (Invitrogen) served as controls.
Isolation of virus particles. Culture supernatants, which were
harvested from the primary cells (single-cell suspensions as well as
sorted B and T cells) and cell lines following LPS or vehicle treatment,
were passed through a 0.45 mm filter (Corning) and centrifuged at
40000 g for 1 h at 4
oC in a TLN100 or NVT65 rotor (Beckman
Coulter) (Yee et al., 1994).
Extraction of RNAs (viral genomic RNA and cellular total RNA)
and RT-PCR. Viral genomic RNA from the virion preparations and
total RNA from cells were isolated using a QIAamp Viral RNA mini
kit (Qiagen) and RNeasy mini kit (Qiagen), respectively, according to
the manufacturer’s instructions. cDNA was synthesized from 1 mlo f
viral genomic RNA or 100 ng of total RNA using Sensiscript reverse
transcriptase (Qiagen). A set of primers, ERV-U1 (59-CGGGCGA-
CTCAGTCTATCGG-39) and ERV-U2 (59-CAGTATCACCAACTC-
AAATC-39), were adopted from a previous report to amplify the 39-
MuLV-ERV U3 region (Tomonaga & Coffin, 1999). The compar-
ability between total RNA samples derived from cells, but not between
genomic RNAs from virus particles, was determined using b-actin
and/or GAPDH as an expression control. The density of the PCR
products from viral genomic RNAs was determined using a Kodak
Gel Logic 200 Imaging System (Carestream Health) and is presented
as mean±SD. Statistical significance was determined by using
Student’s t-test.
Western blot. Protein extracts were prepared from the virus particle
preparations and transfected cells, andWestern blotting wasperformed
as described previously (Cho et al., 2000). Briefly, the membrane was
blocked in 5% non-fat dried milk powder, and goat antibody specific
for gp69/71 of Rauscher MuLV (ViroMed Biosafety Laboratories) and
anti-goat-HRP antibody (Jackson ImmunoResearch Laboratories)
were used to detect MuLV-ERV Env protein. In addition, Western
blot analysis for HSC70 proteinin cellextracts wasperformed using the
same antibody and protocol as described previously (Cho et al., 2004).
Cloning, sequencing and alignment. The PCR amplified U3 bands
were purified using a Qiaquick Gel Extraction kit (Qiagen) and
cloned into pGEM-T Easy vector (Promega). Plasmid DNAs for
sequencing were prepared using a Qiaprep Spin miniprep kit
(Qiagen) and sequencing was performed at the Molecular Cloning
Laboratory (South San Francisco, CA, USA). Initially, a total of 124
MuLV-ERV U3 clones were sequenced, and multiple-alignment
analysis using Vector NTI (Invitrogen) identified 34 unique U3
sequences. Multiple alignments of the LTR sequences of three
recombinant MuLV-ERVs were performed using the Lasergene
program (version 8.0.2; DNASTAR).
Survey of U3 sequences for structural features and transcrip-
tion regulatory elements. Selective structural features (direct
repeats, insertion and unique region) were surveyed in the U3
sequences by comparison to reference sequences (Tomonaga &
Coffin, 1998, 1999). In addition, each unique U3 sequence, which
serves as a promoter, was surveyed for a profile of transcription
regulatory elements using MatInspector (Genomatix) with a core
similarity of 0.90 (Quandt et al., 1995).
In silico mapping of putative MuLV-ERVs. Using each unique
MuLV-ERV U3 sequence as a probe, the corresponding putative
proviral loci were initially identified by surveying the NCBI mouse-
genome database followed by chromosomal mapping of the
individual ERVs’ loci using the Mouse BLAT search program at
http://genome.ucsc.edu. Genomic U3 sequences sharing .98%
identity with a specific U3 probe were mapped for further in silico
mapping of MuLV-ERVs. MuLV-ERV loci were identified based on
the definition that they are ~5 to ~9 kb in size and flanked by LTRs.
The coding potential of each MuLV-ERV was determined by
examining the ORFs for gag, pol and env polypeptides using Vector
D.-N. Kwon and others
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defective) of each polypeptide gene depended on the presence of p12
for gag, RT (reverse transcriptase) for pol and SU (surface domain)
for env. Within each polypeptide gene, if the specified coding
sequence was intact, but the rest was defective, they were determined
to be partial (P). If the specified sequence was not intact, it was
classified as defective (2).
Analyses of PBS, recombination event and integration age.
Putative PBSs were determined by examining a stretch of 18 bp
immediately downstream of the U5 region of the 59 LTR using the
conserved PBS sequences for tRNA as a reference (Harada et al., 1979;
Nikbakht et al., 1985). The integration age was estimated using a
formula of 0.13% mutation rate between flanking LTRs5integration
age of 1 Myr (Sverdlov, 2000; Tristem, 2000). The integration age was
not determined for a single nucleotide difference between flanking
LTRs in consideration of a potential error rate during reverse
transcription, PCR, cloning and sequencing. A stretch of 4–12 bp
flanking each MuLV-ERV was surveyed for TSDs, which indicates
whether the provirus underwent any recombination event.
Construction of recombinant MuLV-ERVs. Among the putative
MuLV-ERVs identified by in silico mapping of the NCBI genome
database, three proviral loci were selected for cloning to test for LPS
stress response. The entire sequence of each target provirus was
amplified from C57BL/6J genomic DNA using a pair of primers
specifically designed with reference to its unique genomic locus and
directly cloned into pCR2.1 expression plasmid (Invitrogen).
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